PRESS-RELEASE ·Filed Mar 26, 2026
Press release · Earnings
Actionable Insight • Neutral
Traders should await the actual 10-K or URD documents for detailed financial performance; this press release alone provides no actionable financial data.
Final — all horizons settled through T+60d ⚠ clustered
DBVT ▼ -21.20% at T+60d
NEUTRAL call -21.20% · α vs SPY -37.27% · entry $20.00 → $15.76
T+1d
-2.20%
call -2.20% · α -1.84%
$19.56
settled 7mo ago
T+5d
+1.80%
call +1.80% · α -2.06%
$20.36
settled 7mo ago
T+20d
+1.95%
call +1.95% · α -10.79%
$20.39
settled 6mo ago
T+60d
-21.20%
call -21.20% · α -37.27%
$15.76
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
DBV Technologies announced the filing of its 2025 Annual Report on Form 10-K and Universal Registration Document, disclosing governance, financial, and auditor information. The release contains no new financial results or operational updates beyond confirming routine regulatory filings.
Key Facts
- DBV Technologies filed its 2025 Annual Report on Form 10-K with the SEC and Universal Registration Document with the AMF.
- The filing includes standard components: financial report, corporate governance report, auditor reports, and details on share buy-back program.
- No new financial data, earnings figures, or operational updates were disclosed in the press release.
- The company continues to focus on VIASKIN® Peanut Patch trials in toddlers and children with food allergies.
Financial Impact
No immediate financial impact — this is a routine disclosure filing.
Risk Factors
- Lack of disclosed financial metrics prevents assessment of 2025 performance.
- Biotech development risk remains high due to reliance on clinical trial outcomes for VIASKIN®.
Market Snapshot
Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263475 |
7 reports for DBVT
33% Hit rate @ T+5 Went positive at some point 1 of 3 best @ T+60▲ +35.47%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $11.76 $9.77 | ▼ −16.92% | ▼ −18.83% | $9.98 (−15.14%) |
Jul 27, 2026 13w ago | S-3ASR | $13.90 $13.50 | ▲ +2.88% | ▲ +3.95% | $9.98 (+28.20%) |
Jul 6, 2026 16w ago | Press Release | $17.35 $15.92 | ▼ −8.24% | ▼ −8.79% | $9.98 (−42.48%) |
Jun 29, 2026 17w ago | 8-K | $16.40 $15.61 | ▼ −4.82% | ▼ −5.42% | $9.98 (−39.15%) |
Apr 30, 2026 25w ago | Press Release | $19.87 $19.73 | ▼ −0.70% | ▼ −3.05% | $9.98 (−49.77%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.98 (−50.10%) |
Mar 26, 2026 30w ago | Press Release | $20.00 $20.36 | ▲ +1.80% | ▼ −2.06% | $9.98 (−50.10%) |
Showing 7 of 7
US Market Status
Market Closed — Opens in 4h 47m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers